TrialBlood2022

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.

Eunice S Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.